Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 88, Issue 5, Pages 2348-2351Publisher
ENDOCRINE SOC
DOI: 10.1210/jc.2002-021942
Keywords
-
Categories
Ask authors/readers for more resources
Hoping to get more insight into a role of vascular endothelial growth factor (VEGF), a putative substance involved in the development of preeclampsia, we measured concentrations of soluble VEGF receptor-1 (sVEGFR-1), a natural antagonist of VEGF, in serum from women with (n = 31) and without (n = 52) preeclampsia. The concentrations of sVEGFR-1 in serum from women with preeclampsia (median 7791 pg/mL) were > 6-fold higher than those from control (1132 pg/mL, p < 0.0001). The levels of sVEGFR-1 decreased markedly after delivery in both groups. Serum sVEGFR-1 levels of non-preeclamptic women were positively correlated with gestational age(r = 0.570 p < 0.0001), whereas those of preeclamptic women exhibited no correlation with gestational age (r = -0.130 p = 0.476). These findings may point to an involvement of sVEGFR-1 in the pathophysiology of preeclampsia possibly by antagonizing of VEGF effects on the formation of placental vasculature and maternal endothelial cell function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available